Efficacy of Different Bacillus of Calmette-Guérin (BCG) Strains on Recurrence Rates among Intermediate/High-Risk Non-Muscle Invasive Bladder Cancers (NMIBCs): Single-Arm Study Systematic Review, Cumulative and Network Meta-Analysis.
Francesco Del GiudiceVincenzo AseroEugenio BolognaCarlo Maria ScornajenghiDalila CarinoVirginia DolciPietro ViscusoStefano SalcicciaAlessandro SciarraDavid D'AndreaBenjamin PradereMarco MoschiniAndrea MariSimone AlbisinniWojciech KrajewskiTomasz SzydełkoBartosz MalkiewiczŁukasz NowakEkaterina LaukhtinaAndrea GallioliLaura S MertensGautier MarcqAlessia CimadamoreLuca AfferiFrancesco SoriaKeiichiro MoriKarl Heinrich TullyRenate PichlerMatteo FerroOctavian Sabin TătaruRiccardo AutorinoSimone CrivellaroFelice CrocettoGian Maria BusettoSatvir BasranMichael L EisenbergBenjamin Inbeh ChungEttore De BerardinisPublished in: Cancers (2023)
We did not identify a BCG stain providing a clinically significant lower BC recurrence rate. While these findings might discourage investment in future head-to-head randomized comparison, we were, however, able to highlight some potential enhanced benefits from the genetically different BCG RIVM, Tice, and Tokyo 172. This evidence would support the use of such strains for future BCG trials in NMIBCs.